At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 161 enrolled
Drug / intervention
Acalabrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib and Pembrolizumab for Follicular Lymphoma (FL) and 12 related conditions. Completed, enrolled 161 participants across 19 sites.
Detailed Summary
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartFeb 2015
Primary CompletionJul 2020
Study CompletionOct 2025
TodayJul 2026
First PostedFeb 12, 2015
Enrollment StartFeb 20, 2015
Primary CompletionJul 14, 2020
Study CompletionOct 27, 2025
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 11.4 years ago
Interventions
Acalabrutinibdrug
Orally Administered (PO)
Pembrolizumabdrug
Intravenous Administered (IV)